IPOGrid
Weekly market reviews and company IPO coverage based on deal terms, demand signals, underwriting, financial performance, and current listing context.
Holtec and Orion180 bring $1.2 billion of IPO demand
The U.S. IPO calendar returned from Labor Day with two consequential roadshows. Holtec Nuclear set a 50 million-share range of $15 to $18, while Orion180 Insurance Group proposed 20 million shares at $15 to $17....
Indivior’s $1 billion payout shifts the Supernus merger math
IPO paperwork advanced, but no clean market handoff followed
The week ended September 6 delivered two effective prospectuses, yet neither gave investors a conventional IPO to price in the aftermarket. Advance JV Group set a fixed $2 offer, but its deal can close with any number...
Aggreko files with $3.4 billion of revenue and a heavy interest bill
Aggreko gave the U.S. pipeline its first institutional-scale filing of the week, returning a global power-rental business to public markets after five years under private-equity ownership. The company applied to list on...
EUROEV clears the SEC, but its restart funding is incomplete
DRC Medicine faces a redemption test at a $350 million equity value
Lyntris cuts price and size, then falls 11.4%
Lyntris delivered the week’s only institutional-scale IPO, and buyers made the defense contractor concede on both price and size. The company and its holders sold 17 million shares at $17.50, raising $297.5 million...
First Breach reaches Nasdaq, but the company gets no new capital
Lyntris cuts its IPO, then falls 11.4% at the open
WATR reaches Nasdaq after a $100 million valuation cut
Vogenx and Londian Wason price at the top
Two issuers cleared the market at the top of their ranges during the week ended August 16, but the results rewarded specificity, not breadth. Clinical-stage biotech Vogenx and Chinese copper-foil producer Londian Wason...
newcleo’s $2.4 billion Nasdaq deal reaches its market test
Braveheart and Latigo lead a $1.17 billion biotech IPO week
Biotech issuers controlled the U.S. IPO tape in the week ended August 9, and the strongest deals did more than get through. Braveheart Bio priced above its range, Latigo Biotherapeutics landed at the top, Attovia...
Braveheart tests $1.35B valuation with Fidelity interest
JMKE's $1 billion IPO meets a skeptical first trade
FOIL’s indicated orders exceed the base IPO
Jersey Mike’s clears $1 billion as IPO buyers hold the line
Jersey Mike’s gave the week its scale and its clearest read on risk appetite. The sandwich franchisor and its shareholders sold 43.48 million shares at $23, the midpoint of the marketed range, for a $1 billion offering....
WISeKey's WQEY listing puts voting control in focus
Attovia asks IPO investors to fund an early itch signal
GYGY heads for Nasdaq as a no-proceeds direct listing, with Streeterville waiting behind it
One IPO priced, two big launches hit the tape, and the small-cap calendar still looks fragile
The week of July 20 to July 26 finally produced one clean handoff from paperwork to public trading, but the broader calendar still looked selective. Scribe Therapeutics priced an upsized IPO at $15 a share for 8.58...
Csquare raised $1.05 billion at $21, below range, to pay down debt while Brookfield kept control
Scribe tests biotech IPO demand with Lilly interest, Sanofi cash and a narrow data runway
Jersey Mike's offers rare restaurant IPO scale, with sponsor control and leverage still central
Csquare cleared, Standard Nuclear cut hard, and the rest of the calendar split between direct listings and biotech filings
The week of July 13 to July 19 finally produced two real cash-raising tests for the U.S. IPO market. Csquare launched (https://www.csquare.com/blog/csquare-inc.-announces-launch-of-initial-public-offering) at 50 million...
Standard Nuclear cuts its IPO ask, keeps the strategic fuel story intact
Weekly IPO Review: SK hynix priced, the rest of the calendar amended
The week of July 6 through July 12 was easy to describe and harder to read through. SK hynix priced 177.9 million ADSs at $149 and raised about $26.5 billion (SEC final prospectus:...
SK hynix brings cornerstone demand and a giant bank group to a $26.5 billion Nasdaq launch
Air Water pushes toward market with a bigger PIPE, lower price, and a large prospective overhang
Columbia's second-step conversion leaves a $281 million to $769 million bank book for Wall Street to clear
Rivian taps the market for a 75 million-share raise tied to its DOE-backed Georgia buildout
Healthcare led Q2 IPO performance while tech dominated proceeds
Q2's clearest shift was that healthcare stopped being just a filing story and started leading the tape. In the quarter's 44 traded IPOs, healthcare and biotech produced 12 deals with average 17.4% first-day and 13.8%...
Selective buyers backed Bending Spoons, Lime, ITG and Sinda while the lower end stayed stuck
The week did not reopen the IPO market in any broad sense. It showed that buyers will still fund size, recognizable sponsors, and straightforward use-of-proceeds stories, but they are not extending that benefit far down...
IQM's Nasdaq debut turns on PIPE cash, not a classic IPO book
Bending Spoons’ IPO funded the acquisition machine, not just the portfolio
SeeQC still needs a $75 million IPO to close its quantum-SPAC merger
DPC priced and traded; Lime, ITG, and CopperTech still need to clear
DPC was the week’s only clean handoff from filing work to public trading. Doncasters launched at $28 to $32, then priced an upsized 27,858,585-share IPO at $33 and raised about $919.3 million before expenses. The same...
DPC priced above range, upsized the deal, and still traded like a shortage asset
Sinda brings Fresnillo, Franco-Nevada and a real bank group to a pre-revenue silver float
CopperTech asks IPO buyers to fund only part of Vedanta's Zambia rebuild
Lime brings real scale to market, but this IPO still has to fix the balance sheet
Two deals reached real trading, but most of the IPO calendar still has more filing motion than market proof
Kardigan gave the week its only unambiguous risk-on signal. The biotech priced an upsized 25 million-share IPO at $16 for $400 million...
DSC’s small Nasdaq IPO has one order big enough to define the book
Freenome’s $240 million PIPE gives FRNM real backing, but the float still looks fragile
AVAT pushed ahead, INNIO launched, and most of late May’s heft still leaned secondary
The week of May 25 to May 31 did not broaden the IPO market so much as clarify its split. The cleanest progression came from special situations, not from a fresh run of conventional operating-company debuts. Avalanche...
Lincoln broke through; the rest of the IPO week stayed in amendment mode
Lincoln International priced its IPO on May 19 (https://www.prnewswire.com/news-releases/lincoln-international-announces-pricing-of-initial-public-offering-302776889.html), and by the next day’s NYSE debut...
Cerebras and Fervo reopened the IPO window. The rest of the calendar still had to fight for it.
Cerebras and Fervo did not just price in the week of May 11 through May 17. They reset the ceiling for what the 2026 IPO market will fund. Cerebras used a May 11 S-1/A to lift its range to $150 to $160 and expand the...
Weekly IPO Review: selective reopening, with HawkEye and Odyssey leading
Selective reopening, not a broad one The week looked better than it felt. HawkEye 360 jumped 30% in its NYSE debut after pricing 16 million shares at $26, the top of its range...
Biotech finally converted the pipeline into cash
The week of April 27 to May 3 finally turned IPO optimism into executed biotech paper. After X-Energy filed its final prospectus for a $1.02 billion IPO...
X-Energy priced and popped. Pershing still set the week's agenda.
X-Energy broke the week open by doing the one thing most of the calendar still has not done: price cleanly and trade well. The company priced 44,254,659 shares at $23, above the $16 to $19 range in its April 20 S-1/A,...
IPO week: Madison Air, Arxis and Kailera reopen the size window
The week of April 13 gave the IPO market a real size test. Madison Air, Arxis, Kailera, AEVEX and Alamar all crossed from filing work into priced offerings, raising roughly $4.5 billion before overallotments. That is...
HMH prices; Elmet and Churchill refill the IPO queue
HMH was the week’s only real handoff from filing work to public trading. The offshore drilling equipment supplier priced 10.52 million Class A shares at $20, inside its $19 to $22 range, raised $210.4 million in gross...